3 low-volatility stocks to invest in now

Adding to recession concerns, US GDP declined for the second straight quarter from April to June. In addition, given the sluggish macroeconomic headwinds, we think it may be wise to increase shares of low-volatility stocks Leidos (LDOS), Incyte (INCY), and The Coca-Cola Company (KO) for now. read on….


Shutterstock.com – Stocknews

Supply chain disruptions, geopolitical crises, rising inflation and the Fed’s aggressive interest rate hike are increasing the prospects of a recession. Other than this, US GDP shrank in the second quarter, marking the second straight quarter decline. According to TD Securities, there more than 50% chance Due to the US recession within the next 18 months.

On the other hand, Jeffrey Roach, chief economist at LPL Financial, said, “The recession has to be significant, widespread and sustained before it can qualify as a recession. The decline is not “significant” in our view.

Nonetheless, market volatility is pervasive, as evidenced by the CBOE Volatility Index’s 27.6% year-over-year gain. As a result, increasing investor interest in low-volatility stocks has resulted in the Invesco S&P 500 Low Volatility ETF (ETF).SPLV) 2.1% profit in the previous month.

We think investors should be interested in these low volatility stocks, Leidos Holdings, Inc. You should consider investing in ,ldos), Insight Corporation (INCY), and The Coca-Cola Company (KO), given the near-term uncertainties.

Leidos Holdings, Inc. ,ldos,

LDOS and its subsidiaries provide services and solutions to the defense, intelligence, civil, and health markets in the United States and internationally. It operates through three segments- Defense Solutions; civil; and health. Its beta is 0.72.

On August 2, 2022, LDOS entered into a definitive agreement with Cobham Limited to acquire the exclusive mission business of Cobham Aviation Services Australia. The acquisition is expected to diversify LDOS’s portfolio and improve business prospects.

LDOS revenue for the second quarter ended July 1, 2022 increased 4.3% year-over-year to $3.60 billion. Its net income grew marginally year-over-year to $172 million. In addition, its non-GAAP EPS came in at $1.59, up 4.6% year-over-year, while adjusted EBITDA grew marginally year-over-year to $366 million.

For 2023, analysts expect LDoS revenue to be $14.93 billion, representing 5.2% year-over-year growth. In addition, the company’s EPS is expected to grow 10.5% year-over-year in 2023 to $7.16. It exceeded EPS estimates in three of the last four quarters. The stock has gained 12.4% year-over-year to close the last trading session at $99.94.

‘ldos’ power rating Reflect on this promising outlook. The stock has an overall B rating, which is the equivalent of a buy in our proprietary rating system. PoWR Ratings assesses stocks based on 118 different factors, each with its own weighting.

In addition, the stock has a B grade for value and stability. inside technology services industry, it is ranked 11th out of 81 stocks. Click Here To view additional power ratings for Growth, Momentum, Sentiment and Quality for the LDoS.

Incyte Corporation (INCY,

Biopharmaceutical company INCY focuses on the discovery, development and commercialization of proprietary therapeutics in the United States and internationally. Its product portfolio includes Jakafi, PemaZire and iClusig. It has 0.66 beta.

On July 19, 2022, the US Food and Drug Administration approved INCY’s Opzelura™ (ruxolitinib) Cream 1.5% for the topical treatment of non-segmental white spots in adult and pediatric patients over 12 years of age. This is a huge leap forward in the treatment of vitiligo, and INCY should benefit from it.

In addition, on June 13, 2022, the US Food and Drug Administration approved INCY and Eli Lilly & Co.LLY) OLUMIANT (baricitinib) tablet, the first systemic treatment in disease for adults with severe alopecia. This breakthrough pill, which has shown tremendous promise in clinical trials, is a milestone achievement and should yield significant returns for the company.

For the second quarter ended June 30, 2022, INCY’s total revenue came in at $911.40 million, up 29.1% year-over-year. Its non-GAAP net income rose 26.6% year-over-year to $226.35 million, while its non-GAAP EPS rose 26.3% year-over-year to $1.01.

Analysts expect INCY’s revenue to grow 15.6% year-over-year to $3.92 billion in 2023. Its EPS is expected to grow 43.7% year-over-year to $4.60 in 2023. Over the past nine months, the stock has gained 8.6%. Close the previous trading session at $72.54.

It should come as no surprise that INCY has an overall A rating, which equates to a strong buy in our proprietary rating system. In addition, it has a B grade for value, sentiment and quality.

INCY is ranked #9 out of 399 stocks Biotechnology industry. Click Here For additional power ratings for INCY (Growth, Speed ​​and Sustainability).

The Coca-Cola Company (KO,

The beverage company, KO, manufactures, markets and sells a variety of non-alcoholic beverages worldwide. The company offers sparkling soft drinks; flavored and enhanced water, sports drinks; juices, dairy, plant-based drinks; tea and coffee; and energy drinks. Its beta is 0.56.

On June 13, 2022, KO and Brown-Forman Corporation announced their global partnership to launch the iconic Jack & Coke cocktail as a branded, ready-to-drink pre-mixed cocktail. This partnership aims to provide consumers with a surreal taste experience by combining two of America’s great drinking classics. Considering the popularity of the brand, the new product is expected to garner a significant market share in no time.

KO’s net operating revenue increased 11.8% year-over-year to $11.32 billion for the second quarter ended July 1, 2022. Its gross profit rose 2.4% year-over-year to $6.50 billion. In addition, its non-GAAP net income came in at $3.06 billion, up 4.4% year-over-year.

For fiscal year 2022, analysts expect KO’s revenue to be $42.13 billion, representing 9% year-over-year growth. In addition, the company’s EPS is expected to grow 6.5% year-over-year to $2.47 in 2022. It exceeded EPS estimates in each of the last four quarters. Over the past year, the stock has risen 12.3% to close the previous trading session at $63.92.

KO’s overall B rating is the equivalent of a buy in our POWR rating system. In addition, the stock has a B grade for consistency and quality.

within A-rated drink Industry, it is ranked #18 out of 35 stocks. Click Here To see additional POWR ratings for Growth, Value, Momentum and Sentiment for the KO.


Shares of LDOS were trading at $100.17 per share, up $0.23 (+0.23%) on Thursday morning. Year-to-date, LDoS has gained 13.49% compared to a 12.30% increase in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty

Riddhima Chakraborty Headshot 1

Riddhima is a financial journalist who has a passion for analyzing financial instruments. with Master’s Degree in EconomicsShe helps investors make informed investment decisions through her insightful comments.

More…

Post 3 low-volatility stocks to invest in now first appeared StockNews.com